Weekly ixabepilone with or without concurrent bevacizumab in the treatment of recurrent endometrial cancer.

被引：0
|
作者：
Roque, Dana Marie [1 ]
Ratner, Elena [1 ]
Silasi, Dan-Arin [1 ]
Azodi, Masoud [1 ]
Schwartz, Peter E. [1 ]
Rutherford, Thomas J. [1 ]
Santin, Alessandro [1 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15526
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Weekly Ixabepilone±Bevacizumab in the Treatment of Platinum/Taxane-Resistant Endometrial & Ovarian Cancers
    Roque, Dana M.
    Schwab, Carlton L.
    English, Diana P.
    Ratner, Elena S.
    Silasi, Dan-Arin
    Azodi, Masoud
    Rutherford, Thomas
    Schwartz, Peter E.
    Santin, Alessandro D.
    REPRODUCTIVE SCIENCES, 2014, 21 (03) : 120A - 120A
  • [2] Successful treatment with weekly paclitaxel in a patient with recurrent endometrial cancer. A case report
    Chang, SJ
    Chen, TC
    Wang, TY
    Hsu, CY
    Chen, HS
    Yang, YC
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2003, 24 (05) : 377 - 378
  • [3] Ixabepilone for the treatment of endometrial cancer
    Marchetti, Claudia
    Piacenti, Ilaria
    Imperiale, Ludovica
    De Felice, Francesca
    Boccia, Serena
    Di Donato, Violante
    Perniola, Giorgia
    Monti, Marco
    Palaia, Innocenza
    Muzii, Ludovico
    Panici, Pierluigi Benedetti
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (05) : 613 - 618
  • [4] Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review
    Roque, Dana M.
    Ratner, Elena S.
    Silasi, Dan-Arin
    Azodi, Masoud
    Rutherford, Thomas J.
    Schwartz, Peter E.
    Nelson, Wendelin K.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2015, 137 (03) : 392 - 400
  • [5] A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer
    Viswanathan, Akila N.
    Lee, Hang
    Berkowitz, Ross
    Berlin, Suzanne
    Campos, Susanna
    Feltmate, Colleen
    Horowitz, Neil
    Muto, Michael
    Sadow, Cheryl A.
    Matulonis, Ursula
    GYNECOLOGIC ONCOLOGY, 2014, 132 (01) : 55 - 60
  • [6] Effects of weekly bevacizumab and paclitaxel/carboplatin with or without sorafenib on heavily pretreated patients with recurrent or persistent cervical cancer.
    Kikuchi, Y.
    Takano, M.
    Goto, T.
    Kouta, H.
    Kikuchi, R.
    Kudoh, K.
    Kita, T.
    Furuya, K.
    Umayahara, K.
    Takizawa, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer
    Aghajanian, Carol
    Filiaci, Virginia
    Dizon, Don S.
    Carlson, Jay W.
    Powell, Matthew A.
    Secord, Angeles Alvarez
    Tewari, Krishnansu S.
    Bender, David P.
    O'Malley, David M.
    Stuckey, Ashley
    Gao, Jianjiong
    Dao, Fanny
    Soslow, Robert A.
    Lankes, Heather A.
    Moore, Kathleen
    Levine, Douglas A.
    GYNECOLOGIC ONCOLOGY, 2018, 150 (02) : 274 - 281
  • [8] Successful treatment of two patients with recurrent endometrial cancer by weekly paclitaxel
    Ota, S
    Sugiyama, T
    Ushijima, K
    Komai, K
    Fujiyoshi, K
    Hirai, N
    Nishida, T
    Kamura, T
    CANCER LETTERS, 2000, 160 (01) : 9 - 12
  • [9] Bevacizumab in endometrial cancer treatment
    Morotti, Matteo
    Menada, Mario Valenzano
    Venturini, Pier Luigi
    Ferrero, Simone
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 649 - 658
  • [10] Recurrent endometrial cancer. An interdisciplinary challenge
    Harms, W.
    Rein, D.
    Strauss, H. -G.
    ONKOLOGE, 2012, 18 (10): : 901 - +
12345